Core Laboratories (CLB) Tops Q4 EPS by 2c, Offers Guidance

Core Laboratories (NYSE: CLB) reported Q4 EPS of $0.20, $0.02 better than the analyst estimate of $0.18. Revenue for the quarter came in at $125.1 million versus the consensus estimate of $107.38 million.

GUIDANCE:

Core Laboratories sees Q1 2022 EPS of $0.16-$0.20, versus the consensus of $0.17. Core Laboratories sees Q1 2022 revenue of $117-122 million, versus the consensus of $109.5 million.

For earnings history and earnings-related data on Core Laboratories (CLB) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low
• InspireMD (NSPR) Tops Q2 EPS by 1c